EHRA PRACTICAL GUIDE European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
نویسندگان
چکیده
Department of Cardiovascular Medicine, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium; Department of Cardiology, Amphia Ziekenhuis, Breda, Netherlands; Department of Cardiology, Klinikum Oldenburg, Oldenburg, Germany; Department of Neurology, Ruprecht Karls Universität, Heidelberg, Germany; Uppsala Clinical Research Center and Dept of Medical Sciences, Uppsala University, Uppsala, Sweden; Clinical Cardiology, St George’s University, London, UK; University of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK; and Department of Cardiology and Angiology, University of Münster, Germany
منابع مشابه
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.
In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients ...
متن کاملEHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in specific clinical situations. This text is an executive summary of a practical guide that the European Heart Rhythm Association (EHRA) has ass...
متن کاملEHRA PRACTICAL GUIDE Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Advisors:, Azhar Ahmad, M.D. (Boehringer Ingelheim Pharma), Jutta Heinrich-Nols, M.D. (Boehringer Ingelheim Pharma), Susanne Hess, M.D. (Bayer Healthcare Pharmaceuticals), Markus Müller, M.D., Ph.D. (Pfizer Pharma), Felix Münzel, Ph.D. (Daiichi-Sankyo Europe), Markus Schwertfeger, M.D. (Daiichi-Sankyo Europe), Martin Van Eickels, M.D. (Bayer Healthcare Pharmaceuticals), and Isabelle Richard-Lor...
متن کاملEuropean Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rh...
متن کاملNew oral anticoagulants: a practical guide for physicians.
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Unlike VKAs, these anticoagulants do not require routine INR monitoring and possess favorable pharmacological properties. The lack of an effective antidote, their cost, or reservations in patients with kidney disease may explain their slow...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013